Diagnosis and management of primary malignant tumors in the upper extremity.

Bone and soft tissue sarcomas of the upper extremity are relatively uncommon. In many cases, they are discovered incidentally during evaluation of traumatic injuries or common ailments such as rotator cuff tendonitis or tennis elbow. Thus, it is important for all orthopedic surgeons to understand the differential diagnosis, workup, and treatment for upper extremity lesions. An appreciation of the clinical and radiographic features of primary malignant lesions aids in identifying patients that need referral to an orthopedic oncologist and a multidisciplinary team.

Physician Training Ultrasound and Accuracy of Diagnosis in Rotator Cuff Tears.

INTRODUCTION: Ultrasonography offers a fast and inexpensive method to evaluate the rotator cuff in the office setting. However, the accuracy of ultrasound is highly user dependent. The purpose of this study is to investigate the learning curve of an orthopaedic surgeon in using ultrasound to diagnose rotator cuff tears. METHODS: A sports medicine fellowship trained orthopaedic surgeon was taught how to perform and interpret an ultrasound examination of the shoulder by a musculoskeletal radiologist. In this prospective study, subjects were patients who presented to the office with shoulder pain suspected to be consistent with rotator cuff pathology, either complete or partial tears. The surgeon was blinded to magnetic resonance imaging (MRI) results and performed the ultrasound after performing a physical exam. Based on ultrasound and exam, the surgeon assessed if the rotator cuff was intact (no tear) or torn (having a partial or full thickness tear). Results were compared to MRI findings and arthroscopic findings (when available), and accuracy was evaluated over time to determine overall accuracy and if significant learning and improvement in accuracy took place over the time period studied. RESULTS: Eighty patients were enrolled in the study; seventy-four had an MRI within 3 months of the ultrasound and were available for evaluation. Nineteen patients underwent ultrasound, MRI, and arthroscopy. Ultrasound was able to accurately diagnose the correct rotator cuff pathology (no tear, a partial thickness tear, or a full thickness tear) in 61% of patients. Ultrasound accurately diagnosed simply the presence or absence of a tear in 74% of patients. There was a general trend toward improved accuracy as the investigator gained experience, with accuracy rates of approximately 51% for the first 40 patients, and 69% for the last 40 patients evaluated, although this difference was not statistically significant (p = 0.154). DISCUSSION: Ultrasound imaging requires significant training and practice to provide a clinically useful level of diagnostic accuracy. The applicability of this procedure for diagnosing primary rotator cuff tears in an orthopaedic office setting may be limited by the time and volume required for the practitioner to approach the accuracy reported for diagnostic ultrasound and MRI in the literature.

Biologic augmentation in rotator cuff repair--should we do it, who should get it, and has it worked?

Rotator cuff tears are a common pathologic entity, and rotator cuff repairs are a frequently performed procedure. Given the high rate of structural failure of repair, biological augmentation of repairs is increasingly important. Biological augmentation primarily enhances the healing response and secondarily provides a mechanical bridge for tension free repair. Understanding biology of tendons and tendon healing aids in determining an optimal environment for repair. The basic principles of rotator cuff repair are aimed at achieving high initial fixation strength of the repair, restoring the anatomic footprint of the cuff tendon, minimizing gap formation, and maintaining mechanical stability until biologic healing occurs. Methods of augmentation come in many different forms and can be categorized by cell type and mechanism of delivery. Cell types include individual growth factors, stem cells, or a combination of both. Vehicles range from in situ delivery, such as microfracture, direct injection, or scaffold materials that are biologic or synthetic.

An analysis of causes of readmission after spine surgery.

STUDY DESIGN: Retrospective review of medical records. OBJECTIVE: We reviewed all early readmissions after elective spine surgery at a single orthopedic specialty hospital to analyze the causes of unplanned readmissions. SUMMARY OF BACKGROUND DATA: Recent advances in techniques and instrumentation have made more complex spinal surgeries possible, although sometimes with more complications. Early readmission rate is being used as a marker to evaluate quality of care. There is little data available regarding the causes of early readmissions after spine surgery. METHODS: Using the hospital's administrative database of patient records from 2007 to 2009, all patients who underwent spine surgery and were readmitted to the hospital within 30 days were identified and broadly categorized as planned (a staged or rescheduled procedure or a direct transfer) or unplanned. Unplanned readmissions were defined to have occurred as a result of either a surgical or a nonsurgical complication. Analysis was focused on 12 common spine procedures based on the principle procedure International Classification of Diseases, Ninth Revision, Clinical Modification code for the patient's initial admission. The readmission rate was calculated for each procedure. RESULTS: A total of 156 early readmissions were identified, of which 141 were unplanned. Of the unplanned readmissions, the most common causes were infection or a concern for an infection (45 patients, 32% of unplanned readmissions), nonsurgical complications (31 patients, 22% of readmissions), complications requiring surgical revision (21 patients, 15% of readmissions), and wound drainage (12 patients, 9% of readmissions). Fifty-seven percent of unplanned readmissions required a return to the operating room (76% of infections or concern for infection). The average length of stay for the unplanned readmissions was 6.5 days. When using the 12 most common procedures based on the International Classification of Diseases, Ninth Revision, Clinical Modification, the early readmission rate was 3.8% (141 early readmissions in 3673 procedures). CONCLUSION: Infection, medical complications after surgery, and surgical complications requiring revision of implants are the primary causes of unplanned early readmissions and spine surgery. Further studies are necessary to identify patients and procedures most associated with readmission.

Management of failed arthroscopic rotator cuff repair.

Most patients experience pain relief and functional improvement following arthroscopic rotator cuff repair, but some continue to experience symptoms postoperatively. Patients with so-called failed rotator cuff syndrome, that is, with continued pain, weakness, and limited active range of motion following arthroscopic rotator cuff repair, present a diagnostic and therapeutic challenge. A thorough patient history, physical examination, and imaging studies (eg, plain radiography, MRI, magnetic resonance arthrography, ultrasonography) are required for diagnosis. Management is determined based on patient age, functional demands, rotator cuff competence, and the presence or absence of glenohumeral arthritis. Treatment options include revision repair, nonanatomic repair with or without biologic or synthetic augmentation, tendon transfer, and arthroplasty.

Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.

BACKGROUND: Pancreaticobiliary malignancies respond poorly to conventional chemotherapy, and novel agents are needed. Dolatstatin-10 is a potent antimitotic pentapeptide isolated from the marine mollusk Dolabella auricularia that inhibits microtubule assembly. We conducted 2 parallel phase II trials of dolastatin-10 in patients with advanced hepatobiliary cancers and pancreatic adenocarcinoma. PATIENTS AND METHODS: Eligible patients had histologically-confirmed metastatic pancreatic adenocarcinoma or metastatic, locally advanced or recurrent cancer of the liver, bile duct or gallbladder, and had received no prior chemotherapy for advanced disease. Dolastatin-10 400 microg/m(2) was administered intravenously by bolus every 21 days. Restaging CT scans were obtained every 2 cycles. RESULTS: Twenty-eight patients (16 hepatobiliary, including 7 hepatomas, 6 cholangiocarcinomas, 2 gallbladder carcinomas, and 12 pancreatic carcinomas) enrolled; 27 were evaluable for response. There were no objective responses. Grade 3/4 neutropenia occurred in 59% of patients and neutropenic fever in 18%. Median and 1-year survival were 5.0 months and 17% for the pancreatic cancer patients, and 3.0 months and 29% for the hepatobiliary patients. Median time to progression was 1.3 months for the pancreatic cancer patients and 1.6 months for the hepatobiliary patients. CONCLUSIONS: Dolastatin-10 is inactive against hepatobiliary and pancreatic carcinomas.